Standardised reporting of burden of disease studies: the STROBOD statement.


Journal

Population health metrics
ISSN: 1478-7954
Titre abrégé: Popul Health Metr
Pays: England
ID NLM: 101178411

Informations de publication

Date de publication:
07 Oct 2024
Historique:
received: 13 04 2024
accepted: 22 09 2024
medline: 8 10 2024
pubmed: 8 10 2024
entrez: 7 10 2024
Statut: epublish

Résumé

The burden of disease (BOD) approach, originating with the Global Burden of Disease (GBD) study in the 1990s, has become a cornerstone for population health monitoring. Despite the widespread use of the Disability-Adjusted Life Year (DALY) metric, variations in methodological approaches and reporting inconsistencies hinder comparability across studies. To tackle this issue, we set out to develop guidelines for reporting DALY calculation studies to improve the transparency and comparability of BOD estimates. The development of the STROBOD statement began within the European Burden of Disease Network, evolving from initial concepts discussed in workshops and training sessions focused on critical analysis of BOD studies. In 2021, a working group was formed to refine the preliminary version into the final Standardised Reporting of Burden of Disease studies (STROBOD) statement, consisting of 28 items structured across six main sections. These sections cover the title, abstract, introduction, methods, results, discussion, and open science, aiming to ensure transparency and standardization in reporting BOD studies. Notably, the methods section of the STROBOD checklist encompasses aspects such as study setting, data inputs and adjustments, DALY calculation methods, uncertainty analyses, and recommendations for reproducibility and transparency. A pilot phase was conducted to test the efficacy of the STROBOD statement, highlighting the importance of providing clear explanations and examples for each reporting item. The inaugural STROBOD statement offers a crucial framework for standardizing reporting in BOD research, with plans for ongoing evaluation and potential revisions based on user feedback. While the current version focuses on general BOD methodology, future iterations may include specialized checklists for distinct applications such as injury or risk factor estimation, reflecting the dynamic nature of this field.

Sections du résumé

BACKGROUND BACKGROUND
The burden of disease (BOD) approach, originating with the Global Burden of Disease (GBD) study in the 1990s, has become a cornerstone for population health monitoring. Despite the widespread use of the Disability-Adjusted Life Year (DALY) metric, variations in methodological approaches and reporting inconsistencies hinder comparability across studies. To tackle this issue, we set out to develop guidelines for reporting DALY calculation studies to improve the transparency and comparability of BOD estimates.
METHODS AND FINDINGS RESULTS
The development of the STROBOD statement began within the European Burden of Disease Network, evolving from initial concepts discussed in workshops and training sessions focused on critical analysis of BOD studies. In 2021, a working group was formed to refine the preliminary version into the final Standardised Reporting of Burden of Disease studies (STROBOD) statement, consisting of 28 items structured across six main sections. These sections cover the title, abstract, introduction, methods, results, discussion, and open science, aiming to ensure transparency and standardization in reporting BOD studies. Notably, the methods section of the STROBOD checklist encompasses aspects such as study setting, data inputs and adjustments, DALY calculation methods, uncertainty analyses, and recommendations for reproducibility and transparency. A pilot phase was conducted to test the efficacy of the STROBOD statement, highlighting the importance of providing clear explanations and examples for each reporting item.
CONCLUSIONS CONCLUSIONS
The inaugural STROBOD statement offers a crucial framework for standardizing reporting in BOD research, with plans for ongoing evaluation and potential revisions based on user feedback. While the current version focuses on general BOD methodology, future iterations may include specialized checklists for distinct applications such as injury or risk factor estimation, reflecting the dynamic nature of this field.

Identifiants

pubmed: 39375690
doi: 10.1186/s12963-024-00347-9
pii: 10.1186/s12963-024-00347-9
doi:

Types de publication

Journal Article Letter

Langues

eng

Sous-ensembles de citation

IM

Pagination

28

Informations de copyright

© 2024. The Author(s).

Références

GBD 2021 Diseases and Injuries Collaborators. Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet. 2024;403(10440):2133–2161. https://doi.org/10.1016/S0140-6736(24)00757-8 . PMID:38642570
O’Donovan MR, Gapp C, Stein C. Burden of disease studies in the WHO European Region-a mapping exercise. Eur J Public Health. 2018;28(4):773–8. https://doi.org/10.1093/eurpub/cky060 . (PMID: 29697771).
doi: 10.1093/eurpub/cky060
Devleesschauwer B, Maertens C, de Noordhout G, Smit SA, Duchateau L, Dorny P, Stein C, Van Oyen H, Speybroeck N. Quantifying burden of disease to support public health policy in Belgium: opportunities and constraints. BMC Public Health. 2014;14(1):1196. https://doi.org/10.1186/1471-2458-14-1196 .
doi: 10.1186/1471-2458-14-1196
Hilderink HBM, Marjanne HD, Plasmans MJJC, Poos PED, Eysink RG. Dutch DALYs, current and future burden of disease in the Netherlands. Arch Public Health. 2020;78(1):85. https://doi.org/10.1186/s13690-020-00461-8 .
doi: 10.1186/s13690-020-00461-8
Porst M, von der Lippe E, Leddin J, Anton A, Wengler A, Breitkreuz J, et al. The burden of disease in germany at the national and regional level. Dtsch Arztebl Int. 2022;119(46):785–92. https://doi.org/10.3238/arztebl.m2022.0314 .
doi: 10.3238/arztebl.m2022.0314
von der Lippe E, Devleesschauwer B, Gourley M, Haagsma J, Hilderink H, Porst M, et al. Reflections on key methodological decisions in national burden of disease assessments. Arch Public Health. 2020;78(1):137. https://doi.org/10.1186/s13690-020-00519-7 .
doi: 10.1186/s13690-020-00519-7
Henrard S, Devleesschauwer B, Beutels P, Callens M, De Smet F, Hermans C, et al. The health and economic burden of haemophilia in Belgium: a rare, expensive and challenging disease. Orphanet J Rare Dis. 2014;9:39. https://doi.org/10.1186/1750-1172-9-39 .
doi: 10.1186/1750-1172-9-39
Murray CJ. Quantifying the burden of disease: the technical basis for disability-adjusted life years. Bull World Health Organ. 1994;72(3):429–45.
Devleesschauwer B, Havelaar AH, Maertens de Noordhout C, Haagsma JA, Praet N, Dorny P, et al. DALY calculation in practice: a stepwise approach. Int J Public Health. 2014;59(3):571–4. https://doi.org/10.1007/s00038-014-0553-y .
doi: 10.1007/s00038-014-0553-y
Charalampous P, Gorasso V, Plass D, Pires SM, von der Lippe E, Mereke A, et al. Burden of non-communicable disease studies in Europe: a systematic review of data sources and methodological choices. Eur J Public Health. 2022;32(2):289–96. https://doi.org/10.1093/eurpub/ckab218 .
doi: 10.1093/eurpub/ckab218
Charalampous P, Pallari E, Gorasso V, von der Lippe E, Devleesschauwer B, Pires SM, et al. Methodological considerations in injury burden of disease studies across Europe: a systematic literature review. BMC Public Health. 2022;22(1):1564. https://doi.org/10.1186/s12889-022-13925-z .
doi: 10.1186/s12889-022-13925-z
Charalampous P, Haagsma JA, Gorasso V, Noguer I, Padron-Monedero A, Sarmiento R, et al. Burden of infectious disease studies in Europe and the United Kingdom: a review of methodological design choices. Epidemiol Infect. 2023;151: e19. https://doi.org/10.1017/S0950268823000031 .
doi: 10.1017/S0950268823000031
Gorasso V, Nazaré Morgado J, Charalampous P, Pires SM, Haagsma JA, Santos JVI, et al. Burden of disease attributable to risk factors in European countries: a systematic literature review. Arch Public Health. 2023;81(1):116. https://doi.org/10.1186/s13690-023-01119-x .
doi: 10.1186/s13690-023-01119-x
Charalampous P, Polinder S, Wothge J, von der Lippe E, Haagsma JA. A systematic literature review of disability weights measurement studies: evolution of methodological choices. Arch Public Health. 2022;80(1):91. https://doi.org/10.1186/s13690-022-00860-z .
doi: 10.1186/s13690-022-00860-z
Haagsma JA, Polinder S, Cassini A, Colzani E, Havelaar AH. Review of disability weight studies: comparison of methodological choices and values. Popul Health Metr. 2014;12:20. https://doi.org/10.1186/s12963-014-0020-2 .
doi: 10.1186/s12963-014-0020-2
Wyper GMA, Grant I, Fletcher E, McCartney G, Fischbacher C, Stockton DL. How do world and European standard populations impact burden of disease studies? A case study of disability-adjusted life years (DALYs) in Scotland. Arch Public Health. 2020;78:1. https://doi.org/10.1186/s13690-019-0383-8 .
doi: 10.1186/s13690-019-0383-8
Stevens GA, Alkema L, Black RE, Boerma JT, Collins GS, Ezzati M, et al. Guidelines for accurate and transparent health estimates reporting: the GATHER statement. Lancet. 2016;388(10062):e19–23. https://doi.org/10.1016/S0140-6736(16)30388-9 .
doi: 10.1016/S0140-6736(16)30388-9
Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, et al. Consolidated health economic evaluation reporting standards (CHEERS) statement. BMJ. 2013;346: f1049. https://doi.org/10.1136/bmj.f1049 .
doi: 10.1136/bmj.f1049
Devleesschauwer B. European burden of disease network: strengthening the collaboration. Eur J Public Health. 2020;30(1):2–3. https://doi.org/10.1093/eurpub/ckz225 .
doi: 10.1093/eurpub/ckz225
Plass D, Hilderink H, Lehtomäki H, Øverland S, Eikemo TA, Lai T, et al. Estimating risk factor attributable burden – challenges and potential solutions when using the comparative risk assessment methodology. Arch Public Health. 2022;80(1):148. https://doi.org/10.1186/s13690-022-00900-8 .
doi: 10.1186/s13690-022-00900-8
Colzani E, Cassini A, Lewandowski D, Mangen MJ, Plass D, McDonald SA, et al. A software tool for estimation of burden of infectious diseases in Europe using incidence-based disability adjusted life years. PLoS ONE. 2017;12(1): e0170662. https://doi.org/10.1371/journal.pone.0170662 .
doi: 10.1371/journal.pone.0170662
Lundkvist A, El-Khatib Z, Kalra N, Pantoja T, Leach-Kemon K, Gapp C, et al. Policy-makers’ views on translating burden of disease estimates in health policies: bridging the gap through data visualization. Arch Public Health. 2021;79(1):17. https://doi.org/10.1186/s13690-021-00537-z .
doi: 10.1186/s13690-021-00537-z
Cuschieri S, Alkerwi A, Economou M, Idavain J, Lai T, Lesnik T, et al. Conducting national burden of disease studies and knowledge translation in eight small European states: challenges and opportunities. Health Res Policy Syst. 2022;20(1):113. https://doi.org/10.1186/s12961-022-00923-1 .
doi: 10.1186/s12961-022-00923-1

Auteurs

Brecht Devleesschauwer (B)

Health Information, Department of Epidemiology and Public Health, Sciensano, Rue Juliette Wytsman 14, 1050, Brussels, Belgium. brecht.devleesschauwer@sciensano.be.
Department of Translational Physiology, Infectiology and Public Health, Ghent University, Merelbeke, Belgium. brecht.devleesschauwer@sciensano.be.

Periklis Charalampous (P)

Department of Public Health, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.

Vanessa Gorasso (V)

Health Information, Department of Epidemiology and Public Health, Sciensano, Rue Juliette Wytsman 14, 1050, Brussels, Belgium.

Ricardo Assunção (R)

Egas Moniz Center for Interdisciplinary Research (CiiEM), Egas Moniz School of Health & Science, Caparica, Portugal.

Henk Hilderink (H)

National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands.

Jane Idavain (J)

Department of Health Statistics, National Institute for Health Development, Tallinn, Estonia.

Tina Lesnik (T)

Department of Chronic Non-Communicable Diseases and Injuries, National Institute of Public Health, Ljubljana, Slovenia.

Milena Santric-Milicevic (M)

Institute of Social Medicine, Faculty of Medicine, University of Belgrade, Belgrade, Serbia.
Laboratory for Strengthening Capacity and Performance of Health Systems and Workforce for Health Equity, Faculty of Medicine, University of Belgrade, Belgrade, Serbia.

Elena Pallari (E)

German Medical Institute, Limassol, Cyprus.

Sara M Pires (SM)

National Food Institute, Technical University of Denmark, Lyngby, Denmark.

Dietrich Plass (D)

Department for Exposure Assessment and Environmental Health Indicators, German Environment Agency, Berlin, Germany.

Grant M A Wyper (GMA)

Clinical and Protecting Health Directorate, Public Health Scotland, Glasgow, UK.
School of Health & Wellbeing, University of Glasgow, Glasgow, UK.

Elena Von der Lippe (E)

Department of Epidemiology and Health Monitoring, Robert Koch Institute, Berlin, Germany.

Juanita A Haagsma (JA)

Department of Public Health, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH